| Market revenue in 2025 | USD 219.0 million |
| Market revenue in 2033 | USD 431.0 million |
| Growth rate | 9% (CAGR from 2026 to 2033) |
| Largest segment | Hospitals |
| Fastest growing segment | CRO |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostic center, Hospitals, CRO, Pharmaceutical Organizations |
| Key market players worldwide | Roche Holding AG ADR, Abbott Laboratories, Thermo Fisher Scientific Inc, Siemens AG, Danaher Corp, BioMerieux SA, Qiagen NV, BD, Merck KGaA, GE Aerospace, Agilent Technologies Inc, Biogenex, Cell Signaling Technology, Bio SB, DiaGenic |
Healthcare in Spain is decentralized into 17 autonomous zones and these zones are responsible for delivery and functioning of healthcare. Tissue diagnostics in Spain are witnessing a healthy growth owing to the launch of newer technologies and increasing presence of bigger pharmaceutical & biotechnological companies.
This is aided by favorable government regulations that are in line with European regulations. Government policies include introduction of newer technologies and reimbursement of these new technologies are boosting the chances of commercialization and thus helping the market growth.
For instance, government is testing reimbursement in hospitals for some personalized medicine tests such as HER2 & KRAS that are supported by pharmaceutical companies. Increasing research, adoption and awareness for precision and personalized medicine is expected to play a key role in market development & commercialization of newer diagnostic and sequencing technologies.
Publish Date: Jun 12, 2026
Last Updated: Aug 26, 2026
No credit card required*
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| BioMerieux SA | View profile | 13,982 | Marcy l’Etoile, Lyon, France, 69280 | www.biomerieux.com |
| Siemens AG | View profile | 321,000 | Werner-von-Siemens-Strabe 1, Munich, BY, Germany, 80333 | www.siemens.com |
| GE Aerospace | View profile | 125,000 | One Financial Center, Suite 3700, Boston, MA, United States, 02111 | www.geaerospace.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Tissue Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Hospitals was the largest segment with a revenue share of 40.55% in 2025.
Horizon Databook has segmented the Spain tissue diagnostics market based on diagnostic center, hospitals, cro, pharmaceutical organizations covering the revenue growth of each sub-segment from 2021 to 2033.
Healthcare in Spain is decentralized into 17 autonomous zones and these zones are responsible for delivery and functioning of healthcare. Tissue diagnostics in Spain are witnessing a healthy growth owing to the launch of newer technologies and increasing presence of bigger pharmaceutical & biotechnological companies.
This is aided by favorable government regulations that are in line with European regulations. Government policies include introduction of newer technologies and reimbursement of these new technologies are boosting the chances of commercialization and thus helping the market growth.
For instance, government is testing reimbursement in hospitals for some personalized medicine tests such as HER2 & KRAS that are supported by pharmaceutical companies. Increasing research, adoption and awareness for precision and personalized medicine is expected to play a key role in market development & commercialization of newer diagnostic and sequencing technologies.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain Tissue Diagnostics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Spain Tissue Diagnostics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
